老虎證券

美股詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務

費森尤斯醫療

22.07
-0.9000-3.92%
盤後：22.150.0800+0.36%19:30 EDT
成交量：125.13萬
成交額：2,780.02萬
市值：117.46億
市盈率：11.54
高：22.68
開：22.67
低：22.05
收：22.97
52周最高：27.64
52周最低：20.02
股本：5.32億
流通股本：3.98億
量比：2.50
換手率：0.31%
股息：0.86
股息率：3.88%
每股收益(TTM):1.91
每股收益(LYR):1.97
淨資產收益率：8.52%
總資產收益率：3.98%
市淨率：0.81
市盈率(LYR):11.19

資料載入中...

總覽公司新聞資訊公告
2023/02/22

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/02/21

企業合併公告

425 - Prospectuses and communications, business combinations
2023/02/14

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/06/29

員工持股計劃

11-K - Annual report of employee stock purchase, savings and similar plans
2022/02/22

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/06/28

員工持股計劃

11-K - Annual report of employee stock purchase, savings and similar plans
2021/02/23

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/10/29

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/10/29

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/06/26

員工持股計劃

11-K - Annual report of employee stock purchase, savings and similar plans
2020/02/20

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2019/10/31

[修訂]年度報告

20-F/A [Amend] - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2019/06/27

員工持股計劃

11-K - Annual report of employee stock purchase, savings and similar plans
2019/06/07

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2019/02/20

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2018/08/15

SEC問詢函

CORRESP [Cover] - Correspondence
2018/07/10

SEC問詢函

CORRESP [Cover] - Correspondence
2018/06/29

員工持股計劃

11-K - Annual report of employee stock purchase, savings and similar plans
2016/12/01

非美公司披露報告

公告-費森尤斯醫療將專注於賬本IFRS報告和停止美國公認會計准則的財務報表
2016/11/17

非美公司披露報告

材料外國發行人的信息披露
更多